Taiwan The co-founder and president of Mycenax Biotech, Dr. Karen Wen details the key lessons learned from the development of their first in-house product TuNEX® and how they have been applied to their second flagship product LusiNEX (tocilizumab). She also details the company’s transition from a platform-driven service provider to a…
Singapore Having recently obtained cGMP from Singapore’s Health Sciences Authority, the founders of PrIME Biologics showcase the role of PrIME Technology in driving plasma self-sufficiency in Asia, while highlighting how this innovative technology is disrupting industry standards of plasma fractionation. Could you please introduce to our international readers the background underlying…
Pharma MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in the upcoming years; investing in the local workforce to support the company’s growth. The headline-making news at the moment is…
Research NIBRT’s projects director discusses the new ‘Biologic’ center for biologics research, business development, training, and commercializing the organisation’s extensive research capabilities. As Projects Director, you are responsible for driving NIBRT’s growth and development, in terms of both research and bioprocessing training. What’s the most exciting opportunity that NIBRT is currently working on?…
Pharma FDI into Irish pharma has almost exclusively targeted in biologics production over the last few years, largely due to Ireland’s skilled workforce of bioprocessing technicians. NIBRT director Dominic Carolan discusses how the institute supports the Irish biopharma industry through training and recruitment solutions, while pursuing research that may help to…
Pharma Philippe Luscan reveals how Sanofi contributes almost USD 6.35 billion net to the French economy; how their five new global business units will drive future growth, and why they are now accelerating their investment in biologics. As the national champion in the healthcare sector, what is the importance of Sanofi…
Pharma The owner of Altis Biologics, Nick Duneas, illustrates the significance of the company’s flagship product, the Altis Osteogenic Bone Matrix (OBM) and how the company plans to commercialize the injectable bone graft substitute on a domestic and international scale moving forward. He also highlights how the Innovation Prize for Africa has…
pharma Pfizer Global Established Products’ BU Head and Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well as the challenges faced by the French biosimilars market and what Pfizer-Hospira is doing to achieve the huge potential in…
Interface Biologics Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined IBI in 2008, what was your initial mandate upon arriving here? My initial mandate was to demonstrate commercial viability. Since…
See our Cookie Privacy Policy Here